OMER, Israel, July 27, 2016 -- Medigus Ltd. (MDGS) (MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that Johns Hopkins Hospital, an integrated global health enterprise and one of the leading health care systems in the United States, has provided an initial purchase order (PO) for the MUSE™ system. The PO covers the cost of a MUSE system console and endoscopic device, which will be available for use on eligible patients suffering from GERD.

 

The Medigus Ultrasonic Surgical Endostapler, or MUSE system, is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device is equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication — the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD).

Company Offers Single-Cycle Solution that can

Replace Steam and Legacy Low-Temperature Sterilization Practices

 

QUÉBEC CITY, July 25, 2016 - TSO3 Inc. (TSX:TOS.TO - News) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, has completed sterile efficacy validation for multiple, heavy-duty battery-powered orthopedic instrument sets in a single sterilization cycle of the Company's STERIZONE® VP4 Sterilizer.

 

These large and heavy instrument sets consist of batteries, attachments, handpieces and inserts. The instrument sets are often "split up" and sterilized in multiple steam cycles or a combination of the traditional steam and legacy low-temperature sterilization (LTS) systems. The STERIZONE® VP4 Sterilizer has been validated to process complete instrument sets in a single cycle -- allowing the instruments to travel together within a hospital and arrive sterile at the operating room together.  This means faster turn-around times, simpler instrument management and cost-effective reprocessing when compared to traditional steam and LTS systems.

Company Pursues Prion Inactivation Claims and Expands Portfolio with Double-Door Option for Revolutionary STERIZONE® VP4 Sterilizer

 

QUÉBEC CITY, July 18, 2016  - TSO3 Inc. (TOS.TO) (« TSO3 » or the « Company »), an innovator in sterilization technology for medical devices in healthcare settings, today announced a series of initiatives in support of a planned European launch of the Company's STERIZONE® VP4 Sterilizer this year.

 

The Company has initiated studies in France in support of obtaining Prion inactivation claims for that market. In addition, the Company has completed development of a double door, or "pass-through", option for the STERIZONE® VP4 Sterilizer which is highly desirable in many European markets.

ST. LOUIS, July 13, 2016 -- Stereotaxis, Inc. (STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the University of Chicago Medicine will implement the Company’s Niobe® ES remote magnetic navigation system as part of its vision to create a cutting-edge arrhythmia technology suite. The University of Chicago Medicine is one of the nation's leading academic medical institutions, consistently ranked among the best hospitals in the nation by U.S. News & World Report. The Center for Arrhythmia Care at the University of Chicago Medicine, led by renowned cardiologist Dr. Roderick Tung, director of the cardiac electrophysiology program, is one of the busiest university-based heart rhythm programs in the Chicago area.

 

“The Niobe system is perhaps the most revolutionary invention in the field of cardiac ablation, enabling remote anatomic mapping of electrical currents and eradication of difficult-to-reach arrhythmias with unparalleled safety and pinpoint precision,” said Tung. “Our acquisition of Stereotaxis’ latest generation remote magnetic navigation platform will enhance a highly respected electrophysiology (EP) program that is regarded as a global leader in ablation therapy, research and education, especially in the treatment of ventricular tachycardia (VT), and will greatly improve patients’ lives.”